Project Summary Without significant additional political leadership, investment and further scientific advance, the global response to HIV/AIDS is not on track to achieve the 2030 goal of ending AIDS as a public health threat. This is due to continued high rates of incident HIV infection in multiple communities, populations, countries, and regions. While HIV science has made remarkable advances, implementation of highly effective prevention and treatment options remains challenging. Taken together, these realities underscore that the HIV response must be global to succeed, that HIV research and training efforts must also be global and multidisciplinary, and that actors in all sectors of the HIV response are needed to address our shared goal of reducing HIV as a threat to global health and individual wellbeing. To respond to this imperative, the 25th International AIDS Conference, AIDS 2024, will convene the HIV community in Munich, Germany, and virtually in July 2024. AIDS 2024 will bring together clinicians and people living with HIV, community leaders and policy makers, basic scientists, junior investigators, donors, journalists, and experts from law, policy and program implementation. This diversity is essential to revitalizing the HIV response, since multi-sectoral and multi-disciplinary work is needed. Munich was also selected as host city to bring a specific focus on Central and Eastern Europe, including Ukraine and the Russian Federation, where the HIV epidemic continues to expand, driven by a lack of access to health services for key populations and exacerbated by the disruption and instability of the war in Ukraine, mass migration and faltering economies. AIDS 2024 aims to: 1. Accelerate scientific discovery to drive innovation across the HIV prevention and treatment cascades, including pathogenesis, transmission, co-morbidities, vaccines, and cure; long-acting oral and injectable treatment and prevention technologies, including rings for prevention; integrated and differentiated models of care; and analyses of structural and economic determinants of health. 2. Advance core components of implementation science research that address the challenges and opportunities of implementing novel prevention and treatment modalities in different populations and contexts, including implementation of long-acting antiretrovirals for prevention and treatment, and in settings of conflict and displacement. 3. Address HIV vulnerability and determinants of disease progression among key and vulnerable populations, including novel interventions and implementation science to reduce stigma and discrimination, including intersectional stigmas of HIV, homophobia, transphobia, and ethnic and racial disparities. 4. Draw attention to enduring gaps in the HIV response, such as areas where greater investment is needed in research and person-centered service delivery, and where the needs of communities remain neglected. 5. Explore complex dynamics of the still expandin...